# Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
Canonical URL: https://biopharmsignal.com/news/VXRT/vaxart-to-host-stockholder-fireside-chat-on-may-8-at-4-30-p-m-et-61bd19ec
Ticker: VXRT
Company: Vaxart
Source: Vaxart
Published: 2026-05-01 12:00 EST
## Summary

Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT)...

## Article Body
Company to report first quarter 2026 financial results on May 7

SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026.

The live fireside chat can be accessed by clicking here or on the Company’s website at www.vaxart.com .

Investors may submit written questions in advance of the conference call to ir@vaxart.com or through the webcast portal.

A replay of the fireside chat webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact Vaxart Media and Investor Relations: FINN Partners IR@vaxart.com
## Recent Company News
- 2026-07-21 12:00 EST — [Vaxart to Participate in BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19) — Source: Vaxart
- 2026-07-17 20:05 EST — [Vaxart Announces Results of Annual Meeting of Stockholders](https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f) — Source: Vaxart
- 2026-07-06 20:01 EST — [Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine](https://biopharmsignal.com/news/VXRT/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-sa-ad993e0f) — Source: Vaxart
- 2026-07-01 20:00 EST — [Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements](https://biopharmsignal.com/news/VXRT/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-a-2ed5b0dd) — Source: Vaxart
- 2026-06-26 12:00 EST — [Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY](https://biopharmsignal.com/news/VXRT/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-com-2bf27563) — Source: Vaxart
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)